Alamar Biosciences' Q2 Revenue Surges 82%; Provides FY26 Revenue Guidance
Alamar Biosciences (ALMR) reported Q2 2026 revenue of $29.4 million, up 82% year over year, driven by consumables up 147% to $15.5 million and instrument revenue up 35% to $7.8 million. Gross margin rose to 60%. The company guided FY26 revenue to $116 million-$120 million and ended Q2 with $256.3 million cash.
How this was made
The 30-second read
Why it matters
Q2 results show accelerating revenue growth led by consumables, and the company’s first full-year 2026 revenue guidance provides a concrete expectation anchor for the remainder of 2026. The main offset is a sharp increase in operating expenses and a wider operating loss.
Market read
Traders can reprice ALMR based on the combination of a large Q2 revenue beat-style growth rate, improved gross margin, and explicit FY26 guidance, despite higher opex and losses.
What to watch
Gross margin improved to 60% on manufacturing efficiencies and mix shift, but the sustainability of that mix (consumables vs services) is the key swing factor for future profitability and valuation.
Background
Alamar Biosciences is a commercial-stage precision proteomics company using its NULISA and ARGO HT systems for multiplex protein biomarker analysis.
Ticker impact
Alamar reported Q2 2026 revenue of $29.4M, up 82%, and issued FY26 revenue guidance of $116M-$120M.
Bullish bias for the next few sessions as traders digest the guidance and product/consumables demand signals; follow-through depends on whether gross margin and consumables growth persist.
The article provides concrete financial results (revenue, gross margin) and explicit FY26 guidance, which are direct drivers for valuation and expectations. However, the widened operating and net losses and higher opex temper the upside.
Market effects
Signals demand strength for commercial-stage proteomics platforms, especially consumables and multiplex panels, which can lift sentiment across similar tools/diagnostics names.
Limited direct regional spillover; primarily a US small-cap biotech/diagnostics sentiment read-through.
Neurodegenerative biomarker profiling expansion (tau and immune panels) may reinforce global interest in proteomics-enabled disease detection datasets.
Counterpoint
The revenue surge may be partially timing-driven, while operating loss and net loss widened sharply, raising the risk that guidance could require continued heavy spend.
Key entities
- companyAlamar Biosciences, Inc.
Reported Q2 2026 financial results, launched new multiplex panels, expanded neurodegenerative datasets, and provided FY26 revenue guidance.
- productNULISAseq Neuro 220 Panel (eMTBR-tau assay)
Commercial multiplexed blood-based immunoassay for eMTBR-tau, available via NULISAseq Neuro 220 and the Technology Access Program.
- productNULISAseq Immune 340 Panel
Broadest multiplexed immune profiling solution launched for translational research and drug development.
- partnershipAlzheimer's Disease Data Initiative and Gates Ventures
Expanded collaboration adding profiling of 86,000 plasma samples, targeting more than 140,000 samples by 2027.
